Medicine and Dentistry
Diagnosis
100%
Patient
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Age
100%
Hormone Therapy
100%
Cohort Analysis
100%
Tamoxifen
87%
Aromatase Inhibitor
87%
Therapeutic Procedure
62%
Hazard Ratio
37%
Overall Survival
37%
Recurrence Free Survival
37%
Woman
25%
Cancer Registry
25%
Breast Cancer
25%
Recurrent Disease
12%
Microenvironment
12%
Proportional Hazards Model
12%
Trastuzumab
12%
Survival
12%
Follow up
12%
Postmenopause
12%
Treatment Duration
12%
Death
12%
Age Groups
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Tamoxifen
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Aromatase Inhibitor
100%
Overall Survival
42%
Recurrence Free Survival
42%
Cancer Registry
28%
Breast Cancer
28%
Randomized Controlled Trial
14%
Recurrent Disease
14%
Trastuzumab
14%
Death
14%
Survival
14%
Hormone Cancer Therapy
14%
Chemotherapy
14%